Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cocrystal Pharma, Inc. on February 10, 2016. The report serves as a current disclosure pursuant to Regulation FD, referencing a press release issued on the same date (Exhibit 99.1). The company is incorporated in Delaware with principal executive offices in Tucker, GA.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing to disclose a press release and does not contain audited financial statements or detailed financial data.
Material Changes
The filing does not detail specific material changes to financial performance or operations within the text provided. The primary event reported is the issuance of a press release, the content of which is not included in this excerpt.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, or contingencies are not detailed in the body of this Form 8-K. Investors are directed to the attached press release (Exhibit 99.1) for the substance of the disclosure.
Key Facts for Investor Verification
- Verify the content of the press release dated February 10, 2016, referenced as Exhibit 99.1.
- Confirm the company's updated principal executive office address in Tucker, GA, noting the former address in Bothell, WA.
- Review subsequent filings for financial data, as this 8-K contains no quantitative financial metrics.